Serum and salivary anti-capsular antibodies in infants and children immunized with the heptavalent pneumococcal conjugate vaccine.
about
Subclass distribution of natural salivary IgA antibodies against pneumococcal capsular polysaccharide of type 14 and pneumococcal surface adhesin A (PsaA) in childrenSalivary antibodies induced by the seven-valent PncOMPC conjugate vaccine in the Finnish Otitis Media Vaccine Trial.Mucosal vaccination against encapsulated respiratory bacteria--new potentials for conjugate vaccines?Bridging phase 2 and phase 3 pneumococcal immunologic data for future combination vaccines.Identification of the targets of cross-reactive antibodies induced by Streptococcus pneumoniae colonization.Protein carriers of conjugate vaccines: characteristics, development, and clinical trials.Phosphorylcholine allows for evasion of bactericidal antibody by Haemophilus influenzae.New pneumococcal vaccines for children.Salivary immune responses to the 7-valent pneumococcal conjugate vaccine in the first 2 years of life.Current state of pneumococcal vaccines.Effects of sample collection and storage methods on antipneumococcal immunoglobulin A in salivaComparative immunogenicity of 7 and 13-valent pneumococcal conjugate vaccines and the development of functional antibodies to cross-reactive serotypes.Inferior quantitative and qualitative immune responses to pneumococcal conjugate vaccine in infants with nasopharyngeal colonization by Streptococcus pneumoniae during the primary series of immunization.Mucosal immunology of vaccines against pathogenic nasopharyngeal bacteria.Association of pneumococcal conjugate vaccination with rates of ventilation tube insertion in Denmark: population-based register studyProspects for a vaccine against otitis media.Neonatal and infantile immune responses to encapsulated bacteria and conjugate vaccines.Systematic review of the effect of pneumococcal conjugate vaccine dosing schedules on immunogenicity.The differential impact of coadministered vaccines, geographic region, vaccine product and other covariates on pneumococcal conjugate vaccine immunogenicity.Agglutination by anti-capsular polysaccharide antibody is associated with protection against experimental human pneumococcal carriage.Global prevailing and emerging pediatric pneumococcal serotypes.Phagocyte subsets and lymphocyte clonal deletion behind ineffective immune response to Staphylococcus aureus.Pneumococcal conjugate vaccine induced IgG and nasopharyngeal carriage of pneumococci: Hyporesponsiveness and immune correlates of protection for carriage.Salivary Anti-50 kDa Antibodies as a Useful Biomarker for Diagnosis of Typhoid Fever.Detection of Salivary IgA Antibodies Against the HlyE Antigen as a Diagnosis of Typhoid Fever.The utility of saliva for the assessment of anti-pneumococcal antibodies: investigation of saliva as a marker of antibody status in serum.Salivary and Serum Antibody Response Against Neisseria meningitidis After Vaccination With Conjugate Polysaccharide Vaccines in Ethiopian Volunteers.Comorbid risk, respondent characteristics and likelihood of pneumococcal vaccination versus no vaccination among older adults in Brazil.Anticapsular Serum Antibody Concentration and Protection against Pneumococcal Colonization among Children Vaccinated with 7-Valent Pneumococcal Conjugate Vaccine
P2860
Q24684017-87EB988B-BE87-415C-9EE7-5FA46ADCEB7DQ24812739-58D99A6C-E3BA-4961-9880-6C04E6209EDDQ28187952-0CECA2AC-3AFC-4E63-8BD5-4C4FF0D708FEQ30665602-FAF9B253-889D-41B1-A3EE-04B375968935Q33826031-BDF485F1-CF1F-4016-98D3-82CE70D2DCCFQ34170021-14F331C7-526D-4BC7-8AB6-EEB1B9F8DCDDQ34186951-B6127C22-A499-4BDC-89A6-FBD08BF7DC41Q34190093-6238E9C7-66BF-420D-BE53-D455C281D646Q34450459-73517FDF-A9E1-4224-9FD5-702DD28F2AC4Q34744239-07DC29F3-5CD0-4C0A-8A71-E64AAA5BE9FFQ34995650-A09463F8-EE77-4001-ABFB-8F2D15568D0CQ35005217-0DA42623-E666-4A51-B8BD-9EDCEC74CFAAQ35199219-6CAF6C79-77BC-47F6-9509-CF29FDB4276FQ35588006-C7616C65-1931-4A30-A187-F31136921820Q35691633-5BA2EED5-FF83-49DA-AB60-2E6101C3F759Q36600356-4D968C76-624D-4996-A880-6F21FAE809B6Q37282316-B64037E5-C740-46D7-9CE9-871A14EE781BQ37613613-81026286-58D5-46E8-9842-52BBABF2112FQ37621061-37F72F56-3525-42A2-937A-AF42D63A6A5DQ37675714-3333D2A6-8234-4A9F-9A8E-BB7373714BF2Q37821484-7C94FB21-CA9C-459E-88B2-D691403F813BQ38494482-0E7A7832-BD37-45CA-AC0F-5CAD3072D0A1Q38652537-63A8926E-CD6E-4619-93CD-DF12BDF13CBEQ40045224-D9A8D682-0870-41D3-B571-54E7BC1B0791Q40093531-2BA0EFF6-699B-4035-A920-90CB47A40225Q40436316-653E0338-DF16-47B8-89ED-8335B47F948EQ53762383-51BC5EAC-D918-4DC4-9A69-75F51C694433Q54486213-008EDA2A-CB18-425C-BFC7-2EA57C5F5F81Q58097241-BDD6FAF0-ED8C-41BA-B6A3-9FEEFB2FBE3F
P2860
Serum and salivary anti-capsular antibodies in infants and children immunized with the heptavalent pneumococcal conjugate vaccine.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh-hant
name
Serum and salivary anti-capsul ...... neumococcal conjugate vaccine.
@en
Serum and salivary anti-capsul ...... neumococcal conjugate vaccine.
@nl
type
label
Serum and salivary anti-capsul ...... neumococcal conjugate vaccine.
@en
Serum and salivary anti-capsul ...... neumococcal conjugate vaccine.
@nl
prefLabel
Serum and salivary anti-capsul ...... neumococcal conjugate vaccine.
@en
Serum and salivary anti-capsul ...... neumococcal conjugate vaccine.
@nl
P2093
P1476
Serum and salivary anti-capsul ...... neumococcal conjugate vaccine.
@en
P2093
P356
10.1097/00006454-200101000-00006
P577
2001-01-01T00:00:00Z